CDK9 inhibitors reduced MCL-1 protein levels and demonstrated antitumor efficacy in a preclinical AML model.75 3) In AML, CDK9 forms distinct mTOR-like (CTOR) complexes in the cytoplasm and nucleus. This evidence concerns the gene MCL1 and acute myeloid leukemia.